45 rows TYME has a less variance in analysts estimates than nearly 100 of all US stocks. The current Tyme Technologies NASDAQTYME price target is 000.Ģ hours agoOTCMKTSEVTZF opened at 1027 on Friday. Tyme Technologies stock price prediction is an act of determining the future value of Tyme Technologies shares using few different conventional methods such as EPS estimation analyst consensus or fundamental intrinsic valuation.
This is 388 less than the trading day before Friday 27th May 2022.
According to 7 analysts the average rating for TYME stock is Buy The 12-month stock price forecast is 969 which is.
Find the latest Tyme Technologies Inc.Įvertz Technologies has a 12 month low of 958 and. The average price target is 000 with a high forecast of 000 and a low forecast of 000. The current price of Tyme Technologies is the price at which Tyme Technologies is currently trading. TYME stock price quote stock graph news analysis. NASDAQTYME Get Rating Director Steve Hoffman sold 78125 shares of the companys stock in a transaction on Tuesday June 21st. That average ranking earns Tyme Technologies Inc an Analyst Rating of 79 which is better than 79 of stocks based on data compiled by InvestorsObserver. This price target is based on 0 analysts offering 12 month price targets for Tyme Technologies in the last 3 months. What is TYMEs Earnings Per Share EPS forecast for 2023-2025. On average analysts give Tyme Technologies Inc a Strong Buy rating.Īccording to 7 stock analysts the average 12-month stock price forecast for TYME stock is 969 which predicts an increase of 362692. Tyme Technologies Inc Stock Forecast BUY SELL NASDAQTYME. Tyme Technologies Incs average analyst price target is higher than 1754 of all US stocks. The average Tyme Technologies stock forecast 2023 represents a 35489 increase from the last price of 0247999995946884. Rooms Shows Rankings Earnings Newsletters Shop. Learn why top analysts are making this price prediction at MarketBeat. NASDAQTYMEs beta value is currently sitting at 104 while the Average True Range indicator is currently displaying 003. The average TYME TECHNOLOGIES stock price prediction forecasts a potential upside of from the current TYME share price of 027. Real-time trade and investing ideas on Tyme Technologies Inc TYME from the largest community of traders and investors. Youll find the Tyme Technologies share forecasts stock quote and buy sell signals belowAccording to present data Tyme Technologiess RFL shares and potentially its market environment have been in bearish. 2 hours agoCitigroup downgraded shares of iRhythm Technologies from a buy rating to a neutral rating and cut their price target for the stock from 18000 to 15500 in a report on Thursday June 9th. Tyme Technologies Incs upside potential average analyst target price relative to current price is higher than 9832 of all US stocks. The successful prediction of Tyme Technologies future price could yield a significant profit. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.Pin On Cheer The average price target is 95 which means analysts expect the stock to rise by 60370 over the next twelve months. The company was formerly known as Global Group Enterprises Corp. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors.
#Tyme stock forecast 2025 trial#
Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States.
0 kommentar(er)
